Novanta Inc. — Q1 2022 Form 10-Q
Business context and period. Novanta supplies photonics, vision and precision-motion technologies to medical and advanced-industrial OEMs. This unaudited quarter ended April 1, 2022; comparisons are with the three months ended April 2, 2021. Amounts below are U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2022 | Prior-year quarter |
|---|---|---|
| Revenue | $204.2 million | $162.6 million |
| Gross profit / margin | $90.3 million / 44.2% | $68.7 million / 42.3% |
| Operating income / margin | $24.3 million / 11.9% | $11.1 million / 6.8% |
| Net income | $18.8 million | $11.3 million |
| Diluted EPS | $0.53 | $0.32 |
| Operating cash flow | $11.3 million | $23.3 million |
| Capital expenditures | $6.3 million | $3.3 million |
Revenue rose 25.6%; net income increased about 66%. Gross margin improved 1.9 percentage points and operating margin 5.1 points. The effective tax rate was 9.1%, versus a tax benefit and 20.8% effective rate in the prior-year quarter.
Cash and cash equivalents were $98.8 million at quarter-end, down from $117.4 million at year-end 2021. Current assets were $375.4 million and current liabilities $183.0 million. Debt carrying value was $417.5 million, compared with $434.5 million at year-end. Management reported $88.7 million of term-loan and $334.5 million of revolver borrowings, with $360.5 million of unused and available revolver capacity. The company was in compliance with its debt covenants.
Material changes and segment results
- Revenue growth reflected $32.8 million from prior-year acquisitions, increased advanced-industrial demand, and a $3.3 million negative foreign-exchange impact. Management attributed demand strength partly to microelectronics and increased industrial manufacturing spending.
- Precision Motion revenue increased 117.8% to $79.4 million, primarily due to acquisitions and stronger demand. Photonics revenue rose 7.3% to $62.8 million. Vision revenue fell 8.3% to $62.1 million, amid materials shortages and continued deferrals of elective procedures.
- Medical products represented approximately 47% of revenue, down from 55%; advanced industrial represented 53%, up from 45%.
- Operating cash flow declined despite higher earnings, mainly due to a $14.9 million inventory build and an $8.4 million bonus payout. Investing cash use was $6.8 million and financing cash use was $22.0 million.
Outlook, risks and unusual items
No formal revenue or earnings guidance is provided in the supplied filing text. Management expects fiscal 2022 capital expenditures of approximately $25–30 million. The ongoing 2020 restructuring program is expected to be substantially completed in Q4 2022, with another $3.5–4.5 million of related charges anticipated.
In March 2022, the company amended its credit agreement, extending maturity to March 10, 2027, changing U.S.-dollar borrowings from LIBOR to SOFR, updating the pricing grid and increasing the uncommitted accordion option to $350 million. The amendment resulted in a $0.6 million write-off of deferred financing costs. Q1 restructuring, acquisition and related costs were a net credit of $1.6 million, including a $2.3 million reduction in prior-acquisition contingent consideration. Contingent consideration liabilities totaled $46.7 million, including $44.0 million related to ATI and payable in 2022.
Management cited supply-chain and component shortages, raw-material, labor and freight inflation, and COVID-related restrictions in China; Suzhou operations were affected to a limited degree. The company said cost increases may not always be fully recoverable through productivity measures or pricing. Russia sales were described as immaterial; longer-term effects of the Ukraine conflict and sanctions remain uncertain. Ordinary-course legal claims were not expected by management to have a material adverse effect, though no assurance was given.
Key facts for investors to verify
- How much of reported growth and Precision Motion performance is acquisition-driven versus organic, and how Vision demand and supply constraints develop.
- Whether inventory growth converts to sales and cash, given lower operating cash flow and the quarter’s working-capital use.
- Debt levels, borrowing costs after the SOFR transition, revolver availability and compliance with covenant requirements.
- The timing and amount of ATI contingent consideration payments, and expected remaining restructuring costs.
- Whether inflation, supply disruptions and China restrictions affect margins, deliveries or customer relationships.